Emmes Rare Disease and Pediatric Center

Orphan Reach was a leading Contract Research Organization (CRO) designed to navigate the complexity of trials in orphan indications. As of the 11th May 2021, Orphan Reach were acquired by Emmes, a global, full-service CRO dedicated to supporting the advancement of public health and biopharmaceutical innovation. Since the acquisition, Orphan Reach has become part of Emmes - functioning as part of Emmes Rare Disease and Pediatric Center. We are here to accelerate the clinical development of orphan drugs and facilitate patient access to urgently needed new treatments for rare conditions. For our customers innovative biotech companies we provide global clinical...

Orphan drugs,rare diseases,rare drugs,orphan development,rare development,clinical research,clinical trials,rare disease trials,and patient recruitment

Emmes rare disease and pediatric center operates in the Biotechnology research industry.

Emmes rare disease and pediatric center's revenue is 11m - 100m

Emmes rare disease and pediatric center has 11 - 50 employees.